What is ADMA & its business profile
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics.
Yahoo Finance
+2
Admabiologics
+2
Its key products include BIVIGAM (an IVIG product for primary humoral immunodeficiency) and ASCENIV (another immunoglobulin therapy).
Yahoo Finance
+2
Admabiologics
+2
The company also operates plasma collection facilities to supply parts of its product pipeline.
Yahoo Finance
+2
Admabiologics
+2
In 2024, they reported strong growth: revenues up ~65% year over year, and Adjusted EBITDA up ~309%.
Admabiologics
In Q1 2025, ADMA reported revenue growth of 40% YoY and EBITDA growth of ~81% YoY.
Admabiologics
In Q2 2025: revenue $122.0 million (14% YoY increase), and GAAP net income of $34.2 million.
Admabiologics
A key development: in April 2025, ADMA received U.S. FDA approval for a yield enhancement process in their immunoglobulin (IG) production, which is expected to boost output (they estimate ~20% increase in output from the same plasma volume) and improve margins.
Admabiologics
+3
Admabiologics
+3
Admabiologics
+3
Strengths & positives
Growth trajectory & profitability
Many biotech companies operate at losses, but ADMA is generating profits and expanding margins, which is a relatively rare and favorable position in the biotech space.
Admabiologics
+4
Investors
+4
Admabiologics
+4
Operational leverage from yield improvements
The FDA-approved yield enhancement means they can get more output from the same plasma inputs, which should help with scaling revenue and improving margins (assuming demand, stability, and regulatory risk are managed).
Admabiologics
+3
Admabiologics
+3
Admabiologics
+3
Analyst sentiment & upside estimates
Several recent analyses point to potential upside. For instance, one source places average target prices in the $20.96 to $35.00 range (implying ~40-60% upside depending on current price) with “Buy” and “Hold” ratings, and no present “Sell” ratings.
Directors Talk Interviews
+2
Directors Talk Interviews
+2
Also, ADMA was spotlighted after its yield process approval: the stock jumped ~12% on the news.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics.
Yahoo Finance
+2
Admabiologics
+2
Its key products include BIVIGAM (an IVIG product for primary humoral immunodeficiency) and ASCENIV (another immunoglobulin therapy).
Yahoo Finance
+2
Admabiologics
+2
The company also operates plasma collection facilities to supply parts of its product pipeline.
Yahoo Finance
+2
Admabiologics
+2
In 2024, they reported strong growth: revenues up ~65% year over year, and Adjusted EBITDA up ~309%.
Admabiologics
In Q1 2025, ADMA reported revenue growth of 40% YoY and EBITDA growth of ~81% YoY.
Admabiologics
In Q2 2025: revenue $122.0 million (14% YoY increase), and GAAP net income of $34.2 million.
Admabiologics
A key development: in April 2025, ADMA received U.S. FDA approval for a yield enhancement process in their immunoglobulin (IG) production, which is expected to boost output (they estimate ~20% increase in output from the same plasma volume) and improve margins.
Admabiologics
+3
Admabiologics
+3
Admabiologics
+3
Strengths & positives
Growth trajectory & profitability
Many biotech companies operate at losses, but ADMA is generating profits and expanding margins, which is a relatively rare and favorable position in the biotech space.
Admabiologics
+4
Investors
+4
Admabiologics
+4
Operational leverage from yield improvements
The FDA-approved yield enhancement means they can get more output from the same plasma inputs, which should help with scaling revenue and improving margins (assuming demand, stability, and regulatory risk are managed).
Admabiologics
+3
Admabiologics
+3
Admabiologics
+3
Analyst sentiment & upside estimates
Several recent analyses point to potential upside. For instance, one source places average target prices in the $20.96 to $35.00 range (implying ~40-60% upside depending on current price) with “Buy” and “Hold” ratings, and no present “Sell” ratings.
Directors Talk Interviews
+2
Directors Talk Interviews
+2
Also, ADMA was spotlighted after its yield process approval: the stock jumped ~12% on the news.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.